Nilvadipine is effective for chronic schizophrenia in a double-blind placebo-controlled study

Kazuo Yamada, Shigenobu Kanba, Iyoko Ashikari, Kimio Ohnishi, Gohei Yagi, Masahiro Asai

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We investigated the efficacy of nilvadipine, a calcium channel inhibitor, for psychiatric symptoms and tardive dyskinesia in 30 patients with chronic schizophrenia in a placebo-controlled double-blind crossover study. The total scores of the brief Psychiatric Rating Scale decreased significantly when the patients were on nilvanipine compared with placebo. Improvement was particularly significant in emotional withdrawal and uncooperativeness. Nilvadipine was not effective, however, for tardive dyskinesia. No adverse effects, such as hypotension, occurred.

Original languageEnglish
Pages (from-to)437-439
Number of pages3
JournalJournal of Clinical Psychopharmacology
Volume16
Issue number6
DOIs
Publication statusPublished - Dec 1 1996
Externally publishedYes

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this